--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--

--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical outcomes with the RNS® System, NAUTILUS results in idiopathic generalized epilepsy (IGE), and the continued evolution of data-driven tools that support treatment planning, patient management and practice development.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.